Research Analysts Set Expectations for Vaxcyte Q1 Earnings

Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q1 2025 earnings estimates for shares of Vaxcyte in a report released on Tuesday, April 1st. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings of ($1.07) per share for the quarter, down from their prior estimate of ($1.01). The consensus estimate for Vaxcyte's current full-year earnings is ($4.21) per share. Leerink Partnrs also issued estimates for Vaxcyte's Q2 2025 earnings at ($1.18) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.37) EPS, FY2025 earnings at ($4.85) EPS, FY2026 earnings at ($5.50) EPS, FY2027 earnings at ($5.59) EPS, FY2028 earnings at ($4.68) EPS and FY2029 earnings at $0.46 EPS.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.14.

PCVX has been the subject of a number of other research reports. Evercore ISI upgraded Vaxcyte to a "strong-buy" rating in a research note on Monday, March 31st. The Goldman Sachs Group dropped their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating on the stock in a research note on Tuesday, April 1st. Bank of America cut their price objective on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating on the stock in a research report on Tuesday, April 1st. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday. Finally, Guggenheim reiterated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. Nine research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company presently has an average rating of "Buy" and an average target price of $136.50.

Remove Ads

Vaxcyte Stock Performance

Shares of PCVX traded down $2.01 during mid-day trading on Thursday, reaching $30.50. The company had a trading volume of 1,678,931 shares, compared to its average volume of 1,681,066. The company has a market capitalization of $3.93 billion, a price-to-earnings ratio of -6.62 and a beta of 1.26. The firm has a 50-day moving average price of $73.42 and a 200 day moving average price of $88.87. Vaxcyte has a 52 week low of $29.57 and a 52 week high of $121.06.

Institutional Trading of Vaxcyte

Large investors have recently added to or reduced their stakes in the business. Whipplewood Advisors LLC purchased a new position in shares of Vaxcyte during the 4th quarter worth $28,000. Smartleaf Asset Management LLC raised its holdings in Vaxcyte by 188.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 398 shares of the company's stock worth $33,000 after purchasing an additional 260 shares during the period. National Bank of Canada FI purchased a new position in Vaxcyte during the fourth quarter valued at $41,000. Blue Trust Inc. grew its holdings in Vaxcyte by 100.0% during the fourth quarter. Blue Trust Inc. now owns 742 shares of the company's stock valued at $61,000 after purchasing an additional 371 shares during the period. Finally, Parallel Advisors LLC grew its holdings in Vaxcyte by 203.6% during the first quarter. Parallel Advisors LLC now owns 1,597 shares of the company's stock valued at $61,000 after purchasing an additional 1,071 shares during the period. 96.78% of the stock is currently owned by institutional investors.

Insider Activity

In other Vaxcyte news, COO Jim Wassil sold 8,000 shares of the business's stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $86.22, for a total transaction of $689,760.00. Following the completion of the sale, the chief operating officer now directly owns 205,695 shares in the company, valued at $17,735,022.90. The trade was a 3.74 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Teri Loxam sold 6,250 shares of the stock in a transaction that occurred on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total transaction of $531,937.50. Following the completion of the transaction, the director now owns 7,175 shares in the company, valued at $610,664.25. This trade represents a 46.55 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 38,250 shares of company stock valued at $3,170,738 over the last three months. Insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.